Omada Health, Inc. (OMDA) Price & Analysis

Compare

147 Followers

OMDA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$14.14 - $28.40

Previous Close$18.29

Volume2.54M

Average Volume (3M)433.94K

Market Cap

$1.23B

Enterprise Value$855.79M

Total Cash (Recent Filing)$223.15M

Total Debt (Recent Filing)$29.97M

Price to Earnings (P/E)―

Beta5.87

Next Earnings

Aug 07, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding57,574,920

10 Day Avg. Volume365,999

30 Day Avg. Volume433,944

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue7.36

Enterprise Value/Gross Profit11.87

Enterprise Value/Ebitda-86.39

Forecast

1Y Price Target

$26.00

Price Target Upside21.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

EarningsThe company’s first earnings report showed significant proof of performance, with gross margin expanding significantly and the majority of revenue upside contributing to EBITDA.

Market PositionOmada Health is considered a winner in the Digital Health 2.0 framework, suggesting a strong position in the evolving market.

Technology And InnovationThe adoption of GLP-1 Care Track, AI, and multi-condition sales are expected to drive significant revenue and margin growth.

Bears Say

Investor ConcernsOMDA’s stock performance reflects investor concerns over durability of growth and the ability to scale businesses profitably.

Technical WeaknessThe weakness in OMDA appears to be technically driven, setting up an attractive risk/reward ahead of what should be a solid Q2 earnings print.

Omada Health, Inc. News

Five new option listings and one option delisting on August 22nd

New option listings for August 22nd include Tradr 2X Long LRCX Daily ETF (LRCU), Mill City Ventures III...

3d ago

VNM

ENZB

Omada Health price target raised to $28 from $27 at Canaccord

Canaccord raised the firm’s price target on Omada Health (OMDA) to $28 from $27 and keeps a Buy...

17d ago

OMDA

Omada Health price target raised to $24 from $21 at Barclays

Barclays raised the firm’s price target on Omada Health (OMDA) to $24 from $21 and keeps an Overweight...

17d ago

OMDA

Omada Health sees FY25 revenue $235M-$241M, consensus $221.84M

Sees FY25 adjusted EBITDA loss $5M-$9M. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

18d ago

OMDA

Omada Health reports Q2 EPS (24c), consensus (13c)

Reports Q2 revenue $61.37M, consensus $55.45M. “I’m proud of our second quarter results, with 49% year-over-year revenue growth,...

18d ago

OMDA

Omada Health, Inc.: Strong Market Position and Growth Potential Justify Buy Rating

Omada Health, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan MacDonald...

17d ago

OMDA

Omada Health Reports Strong Q2 2025 Growth

Omada Health, Inc. ( ($OMDA) ) has released its Q2 earnings. Here is a breakdown of the information...

17d ago

OMDA

Omada Health’s Strategic Partnerships and AI Leverage Drive Growth and Profitability Outlook

Canaccord Genuity analyst Richard Close maintained a Buy rating on Omada Health, Inc. yesterday and set a price...

28d ago

OMDA

Omada Health, Inc.: A Promising Buy Amid Technical Weakness and Growth Potential

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Omada Health, Inc.,...

1M ago

OMDA

Goldman Sachs Beats the Drum on These 2 ‘Strong Buy’ Stocks

After a volatile start to the year, the stock market appears to be regaining its footing. While the...

2M ago

OVV

OMDA

Nike upgraded, Sportradar initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Omada Health initiated with a Buy at Canaccord

Canaccord analyst Richard Close initiated coverage of Omada Health (OMDA) with a Buy rating and $27 price target...

2M ago

OMDA

Omada Health initiated with a Buy at Needham

Needham initiated coverage of Omada Health (OMDA) with a Buy rating and $23 price target The firm says...

2M ago

OMDA

Omada Health initiated with an Overweight at Barclays

Barclays initiated coverage of Omada Health (OMDA) with an Overweight rating and $21 price target. Omada’s digital health...

2M ago

OMDA

TDOC

OMDA FAQ

What was Omada Health, Inc.’s price range in the past 12 months?

Omada Health, Inc. lowest stock price was $14.14 and its highest was $28.40 in the past 12 months.

What is Omada Health, Inc.’s market cap?

Omada Health, Inc.’s market cap is $1.23B.

When is Omada Health, Inc.’s upcoming earnings report date?

Omada Health, Inc.’s upcoming earnings report date is Aug 07, 2025 which is 18 days ago.

How were Omada Health, Inc.’s earnings last quarter?

Omada Health, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.122.

Is Omada Health, Inc. overvalued?

According to Wall Street analysts Omada Health, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Omada Health, Inc. pay dividends?

Omada Health, Inc. does not currently pay dividends.

What is Omada Health, Inc.’s EPS estimate?

Omada Health, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Omada Health, Inc. have?

Omada Health, Inc. has 57,574,920 shares outstanding.

What happened to Omada Health, Inc.’s price movement after its last earnings report?

Omada Health, Inc. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went down -2.261%.

Which hedge fund is a major shareholder of Omada Health, Inc.?

Currently, no hedge funds are holding shares in OMDA

Omada Health, Inc. Stock Smart Score

Outperform

Company Description

Omada Health, Inc.

Omada Health, Inc. is a digital health company that specializes in chronic disease management and prevention. The company focuses on providing evidence-based health programs designed to help individuals manage conditions such as diabetes, hypertension, and obesity. Utilizing a combination of personalized coaching, digital tools, and data analytics, Omada aims to improve health outcomes for its users while reducing healthcare costs for employers and health plans. Its core products include comprehensive digital health programs that support lifestyle changes through behavioral health interventions and remote monitoring.

Omada Health, Inc. (OMDA) Earnings & Revenues

Historic Earnings Reports

OMDA Earnings Call

Q2 2025

0:00 / 0:00

OMDA Stock 12 Month Forecast

Average Price Target

$26.00

▲(21.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","31":"$31","19.75":"$19.75","23.5":"$23.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,19.75,23.5,27.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.38,18.35076923076923,19.32153846153846,20.29230769230769,21.263076923076923,22.23384615384615,23.204615384615384,24.175384615384615,25.146153846153844,26.116923076923076,27.087692307692308,28.058461538461536,29.029230769230768,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.38,18.04307692307692,18.706153846153846,19.369230769230768,20.03230769230769,20.695384615384615,21.358461538461537,22.021538461538462,22.684615384615384,23.347692307692306,24.01076923076923,24.673846153846153,25.336923076923078,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.38,17.58153846153846,17.783076923076923,17.984615384615385,18.186153846153847,18.38769230769231,18.589230769230767,18.79076923076923,18.99230769230769,19.193846153846152,19.395384615384614,19.596923076923076,19.798461538461538,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.6,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >